Inventor

BEARSS DAVID J

US50 patents

⚠️ This page may combine multiple inventors who share the name “BEARSS DAVID J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BEARSS DAVID J

TOLERO PHARMACEUTICALS INC

Alvocidib prodrugs having increased bioavailability

Predicting response to alvocidib by mitochondrial profiling

Alvocidib prodrugs having increased bioavailability

Profiling peptides and methods for sensitivity profiling

Profiling peptides and methods for sensitivity profiling

Combination therapies for treatment of cancer

Predicting response to alvocidib by mitochondrial profiling

Combination therapies for treatment of cancer

Alvocidib prodrugs having increased bioavailability

Predicting response to alvocidib by mitochondrial profiling

JAK2 and ALK2 inhibitors and methods for their use

Profiling peptides and methods for sensitivity profiling

JAK1 and ALK2 inhibitors and methods for their use

BEARSS DAVID J

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase

Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors

Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same

Oxo-imidazolyl compounds

Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase

SUMITOMO PHARMA ONCOLOGY INC

Treatment of acute myeloid leukemia (AML) with venetoclax failure

Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

Alvocidib prodrugs having increased bioavailability

Compositions comprising PKM2 modulators and methods of treatment using the same

AXL kinase inhibitors and use of the same

Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

SUPERGEN INC

Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors

Axl kinase inhibitors

Quinoline derivatives for modulating DNA methylation

Quinoline derivatives for modulating DNA methylation

Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same

UNIV UTAH RES FOUND

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

UNIV ARIZONA

Substituted tricyclic compounds as protein kinase inhibitors

Substituted tricyclic compounds as protein kinase inhibitors

Substituted tricyclic compound as protein kinase inhibitors

Substituted tricyclic compounds as protein kinase inhibitors

NEUROPRO TECHNOLOGIES INC

Bone growth compositions and methods

Spinal fusion using an HMG-CoA reductase inhibitor

REMINGTON BENJAMIN J

Ankle and foot bone growth compositions and methods

Bone growth compositions and methods

SUMITOMO DAINIPPON PHARMA ONCOLOGY INC

Combination therapies for treatment of cancer

Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

VANKAYALAPATI HARIPRASAD

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

UNIV ARIZONA STATE

Protein kinase inhibitors

HURLEY LAURENCE H

Substituted tricyclic compounds as protein kinase inhibitors

BIOLEXIS THERAPEUTICS INC

CDK9 inhibitors